Richard Stanley Bedlack

Richard Stanley Bedlack

Professor of Neurology

External Address: 
932 Morreene Rd Room234, Durham, NC 27705
Internal Office Address: 
Duke Box 3333, Durham, NC 27710
Phone: 
919.668.2839

Overview

1. Investigator-initiated and multi-center clinical trials testing new treatments for amyotrophic lateral sclerosis and diabetic neuropathy.

2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.

3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.

Education & Training

  • EMG Fellow, Medicine, Duke University 1999 - 2000

  • Neurology Resident, Medicine, Duke University 1996 - 1999

  • Medical Intern, Medicine, Duke University 1995 - 1996

  • M.D., University of Connecticut 1995

  • Ph.D., University of Connecticut 1995

Selected Grants

Healy ALS Platform study - Regimen E ¿ Trehalose TO#10 awarded by Massachusetts General Hospital (Principal Investigator). 2021 to 2023

Healey ALS Platform Trial Open Label Extension Zilucoplan awarded by Massachusetts General Hospital (Principal Investigator). 2020 to 2023

Potential Role of the Gut Microbiome in ALS Progression and Reversals awarded by Augie's Quest to Cure ALS (Principal Investigator). 2021 to 2022

Potential Role of the Gut Microbiome in ALS Progression awarded by Martha Olson-Fernandez Foundation (Principal Investigator). 2021 to 2022

ALS Telemedicine awarded by Amyotrophic Lateral Sclerosis Association (Principal Investigator). 2021 to 2022

The Duke ALS Association Certified Center awarded by Amyotrophic Lateral Sclerosis Association (Principal Investigator). 2018 to 2022

I AM ALS awarded by Massachusetts General Hospital (Principal Investigator). 2021

Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE) awarded by University of Miami (Principal Investigator). 2019 to 2021

Pages

Bedlack, R. S., et al. “Accessing Investigational Products Outside of a Trial: Considerations for Neuromuscular Providers.” Current Treatment Options in Neurology, vol. 23, no. 12, Dec. 2021. Scopus, doi:10.1007/s11940-021-00697-x. Full Text

Oskarsson, Björn, et al. “MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design.Neurodegenerative Disease Management, vol. 11, no. 6, Dec. 2021, pp. 431–43. Epmc, doi:10.2217/nmt-2021-0042. Full Text

Bedlack, Richard, et al. “ALSUntangled 59: Tamoxifen.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, vol. 22, no. 7–8, Nov. 2021, pp. 595–98. Epmc, doi:10.1080/21678421.2021.1876731. Full Text

Bedlack, Richard, et al. “ALSUntangled #63: ketogenic diets.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, Oct. 2021, pp. 1–5. Epmc, doi:10.1080/21678421.2021.1990346. Full Text

Galea, Marinella D., et al. “Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID-19.Muscle & Nerve, vol. 64, no. 4, Oct. 2021, pp. E18–20. Epmc, doi:10.1002/mus.27373. Full Text

Cudkowicz, Merit, et al. “Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.The Lancet. Neurology, vol. 20, no. 10, Oct. 2021, pp. 821–31. Epmc, doi:10.1016/s1474-4422(21)00242-8. Full Text

Choi, Philip J., et al. “Continuing Non-Invasive Ventilation During Amyotrophic Lateral Sclerosis-Related Hospice Care Is Medically, Administratively, and Financially Feasible.The American Journal of Hospice & Palliative Care, vol. 38, no. 10, Oct. 2021, pp. 1238–41. Epmc, doi:10.1177/1049909120982291. Full Text

Li, Xiaoyan, and Richard Bedlack. “COVID-19-accelerated disease progression in two patients with amyotrophic lateral sclerosis.Muscle & Nerve, vol. 64, no. 3, Sept. 2021, pp. E13–15. Epmc, doi:10.1002/mus.27351. Full Text

ALSUNTANGLED GROUP, Paul. “ALSUntangled #61: melatonin.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, May 2021, pp. 1–4. Epmc, doi:10.1080/21678421.2021.1927103. Full Text

Pages

Bedlack, Richard S., et al. “Scrutinizing enrollment in ALS clinical trials: Room for improvement?Neurology, vol. 70, no. 11, LIPPINCOTT WILLIAMS & WILKINS, 2008, pp. A344–A344.

Bedlack, R. S., and S. Torres. “Multifocal motor neuropathy with upper motor neuron signs.” Muscle & Nerve, vol. 34, no. 4, JOHN WILEY & SONS INC, 2006, pp. 514–514.

Bedlack, R. S., et al. “Apolipoprotein E genotype is a risk factor for diabetic neuropathy.” Annals of Neurology, vol. 52, no. 6, WILEY-LISS, 2002, pp. 866–866.

Gross, E., et al. “Fluorescent imaging of membrane potential components.” Analytical Use of Fluorescent Probes in Oncology, edited by E. Kohen and J. G. Hirschberg, vol. 286, PLENUM PRESS DIV PLENUM PUBLISHING CORP, 1996, pp. 249–56.

BEDLACK, R. S., et al. “ENDOGENOUS ELECTRIC-FIELDS WITHIN THE NEURONAL PLASMALEMMA - NONUNIFORMITIES SUGGESTING DIFFERENTIAL VOLTAGE-DEPENDENCE.” Biophysical Journal, vol. 66, no. 2, BIOPHYSICAL SOCIETY, 1994, pp. A387–A387.

GROSS, E., et al. “DUAL-WAVELENGTH RATIOMETRIC FLUORESCENCE MEASUREMENT OF THE MEMBRANE DIPOLE POTENTIAL.” Biophysical Journal, vol. 66, no. 2, BIOPHYSICAL SOCIETY, 1994, pp. A387–A387.

BEDLACK, R. S., et al. “ELECTRIC FIELD-BIASED N1E-115 GROWTH CONE FILOPODIAL PROTRUSIONS ARE INHIBITED BY VERAPAMIL.” Biophysical Journal, vol. 64, no. 2, BIOPHYSICAL SOCIETY, 1993, pp. A101–A101.